Exscientia has taken full ownership of its oral CDK7 inhibitor candidate, buying out partner GT Apeiron for $20 million. The AI-enabled biotech plans to advance the molecule into a breast cancer ...

The last time I wrote about Recursion Pharmaceuticals (RXRX) it was with respect to a Seeking Alpha article entitled "Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245". In ...

Syros Announces Update on Selective CDK7 Inhibitor Portfolio Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 ...

Malfunctioning of the enzyme CDK7 is crucial to many cancers, making drugs that target it a high priority. Despite some demonstrated success, the mechanism by which these drugs work has been a mystery ...

Blocking a protein known as CDK7 could prevent heart damage associated with a commonly used cancer chemotherapy medication, according to a study led by scientists at Washington State University.

Immunohistochemical staining Hematoxylin-Eosin, highlights a malignant proliferate tumor (adnocarcinoma), adipose tissue (abdominal fat) infiltrated by a malignant lesion of pancreatic origin. Nerve ...

For organs to develop, grow and regenerate, cells must proliferate. But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge. New CU Boulder research, published in the ...